Showing 1051-1060 of 1204 results for "".
- Industry Responds to COVID-19: Biopelle, Galderma US Aestheticshttps://modernaesthetics.com/news/industry-responds-to-covid-19-biopelle-galderma-us-aesthetics/2473063/Biopelle One bright spot for many aesthetic practices during the COVID-19 pandemic has been persistent and perhaps increased demand for skincare. Biopelle has responded to support physicians who wish to dispense their products. “We offer a ski
- Soliton Receives Best New Technology Awardhttps://modernaesthetics.com/news/soliton-named-best-new-technology/2473062/Soliton's Rapid Acoustic Pulse (RAP) device received the Best New Technology Award from the Aesthetic Industry Association (AIA). The Soliton RAP device, which uses proprietary design acoustic shockwaves to mechanically disrupt targeted cellular structures in a completely
- ASDS Issues New Recommendations on Preventing and Treating Filler Complicationshttps://modernaesthetics.com/news/asds-issues-new-recommendations-on-preventing-and-treating-filler-complications/2473060/The American Society for Dermatologic Surgery (ASDS) Multispecialty Soft-tissue Fillers Guideline Task Force has
- Pulse Biosciences Gets FDA Clearance for CellFXhttps://modernaesthetics.com/news/pulse-biosciences-gets-fda-clearance-for-cellfx/2473058/The FDA has cleared the CellFX® System from Pulse Biosciences, Inc. for dermatologic procedures requiring ablation and resurfacing of the skin, and a controlled commercial launch will soon beginning in the US with a of select group of leaders in aesthetic dermatology. The
- Business News: Dominion Aesthetic Technologies Closes $23.7 Million Series B Financinghttps://modernaesthetics.com/news/business-news-dominion-aesthetic-technologies-closes-237-million-series-b-financing/2473052/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- Fat Loss Accelerates Facial Aging, Not Gravityhttps://modernaesthetics.com/news/fat-loss-accelerates-facial-aging-not-gravity/2473051/The real culprit behind facial aging may be the loss of fat both near the surface of the skin and in deeper areas, not gravity or sagging, finds a
- Pulse Biosciences Receives European Clearance for CellFX Systemhttps://modernaesthetics.com/news/pulse-biosciences-receives-european-clearance-for-cellfx-system/2473050/Pulse Biosciences, Inc. will proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU), now that it has received CE mark for the system. The European clearance is for the treatment of general dermatologic conditions, includi
- Meet CoolSculpting Elitehttps://modernaesthetics.com/news/meet-coolsculpting-elite/2473048/Allergan Aesthetics, an AbbVie company, is launching CoolSculptingElite, its next generation fat reduction system with applicators designed to complement the body's natural curves. The system will launch with a new applicator collection, which includes seven different shapes a
- Candela Rolls Out Frax Prohttps://modernaesthetics.com/news/candela-rolls-out-frax-pro/2473047/Candela’s Frax Pro system is now available. This platform features Frax 1550 and the novel Frax 1940 applicators. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in
- Allergan Aesthetics Enters Into Option to Acquire Cypris Medicalhttps://modernaesthetics.com/news/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical/2473045/Allergan Aesthetics, an AbbVie company has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercis